RA
TEVA icon

Ransom Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

Ransom Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.68K Hold
150
– – ﹤0.01% 382
2025
Q3 		$3.03K Hold
150
– – ﹤0.01% 273
2025
Q2 		$2.51K Hold
150
– – ﹤0.01% 299
2025
Q1 		$2.31K Hold
150
– – ﹤0.01% 309
2024
Q4 		$3.31K Hold
150
– – ﹤0.01% 382
2024
Q3 		$2.7K Hold
150
– – ﹤0.01% 384
2024
Q2 		$2.44K Hold
150
– – ﹤0.01% 378
2024
Q1 		$2.12K Buy
+150
New +$1.89K ﹤0.01% 318

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ransom Advisory's TEVA Position: Q4 2025 in Review

Ransom Advisory held its Teva Pharmaceuticals (TEVA) position steady in Q4 2025 at 150 shares worth $4.68K. The position accounts for ﹤0.01% of the portfolio, ranked #382.

Ransom Advisory first reported a position in TEVA in Q1 2024 and has held it in 8 quarters since. 630 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Ransom Advisory held 150 shares of Teva Pharmaceuticals worth $4.68K as of Q4 2025.
  • Ransom Advisory left its Teva Pharmaceuticals share count unchanged in Q4 2025.
  • Teva Pharmaceuticals made up ﹤0.01% of Ransom Advisory's portfolio in Q4 2025, its #382 holding.
  • Ransom Advisory first reported a position in Teva Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • 630 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Ransom Advisory's 13F filing for Q4 2025, filed 6 Jan 2026.